Related Experiment Video
Updated: Jul 12, 2026

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and
Jörg Wischhusen1, Anne Waschbisch, Heinz Wiendl
1Department for Obstetrics and Gynecology, Julius-Maximilians-University Würzburg, School of Medicine, Josef-Schneider-Strasse 4, 97080 Würzburg, Germany.
Abstract:
There is strong evidence to support a role for non-classical MHC class I (class Ib) molecules, most notably HLA-E and HLA-G in tumour immune escape. In this article, we summarize the current knowledge on their expression, regulation and functional relevance in various malignancies, particularly brain tumours. Special emphasis is devoted to the phenomenon that these tolerogenic molecules are expressed by non-transformed cells that are found in close neighborhood to tumour cells representing either parenchymal cells or immune cells attracted to the tumour microenvironment. Here they may act as "natural" or "inducible" suppressors of anti-tumoural immune responses. We thus speculate about the role of HLA-G expressing T cells, a novel population of natural regulatory cells that was identified recently. It is suggested that various cell types within a tumour cooperate in order to inhibit anti-tumour immunity-and that immunetolerogenic HLA-G may play a major role in this context.
Related Concept Videos
Tumor Immunotherapy
Cell-mediated Immune Responses
Mitogens and the Cell Cycle
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
